An experimental Eli Lilly & Co. lung-cancer drug hasn’t reached the market, but some doctors are already weighing in on how much it should cost—arguing the price should be below average because the drug extended patient lives by only six to seven weeks in a clinical trial.
from WSJ.com: US Business http://ift.tt/1UfbQzq
via IFTTT
No comments:
Post a Comment